Preclinical data from the first vaccine candidate, CV2CoV, has recently been published in Nature Communications. CureVac and GSK expect to progress the second-generation vaccine candidate into clinical testing in the third quarter of 2021, with the goal of introducing the vaccine in 2022, subject to regulatory approval. CureVac will host an investors and analyst webcast and conference call on Thursday, July 1, 2021 at 2:00 p.m. CET / 8:00 a.m. EDT.